<DOC>
	<DOC>NCT01169701</DOC>
	<brief_summary>The objective of the study is to compare the cardiovascular profile of an everolimus and mycophenolic acid immunosuppressive regimen with a calcineurin inhibitor and mycophenolic acid regimen in maintenance renal transplant patients</brief_summary>
	<brief_title>24 Months Follow-up, Two Arm Study to Compare the Cardiovascular Profile in a Regimen With Everolimus + Mycophenolic Acid (MPA) Versus (vs.) a Regimen of CNI+MPA in Maintenance Renal Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>Received kidney transplant &gt; 6 months and &lt; 3 years prior to study enrollment Receiving immunosuppressive regimen that includes tacrolimus and mycophenolic acid Between 18 and 70 years of age Willing to provide written informed consent Patients with an actual serum creatinine ≥ 2 mg/dl and/or eGFR≤ 40 ml/min and/or proteinuria≥ 500mg/day Patients who suffered from severe humoral and/or cellular rejection (≥ BANFF IIb, recurrent acute rejection or steroid resistant acute rejection in the previous years Patients who have severe hypercholesterolemia (&gt;350 mg/dL; &gt;9 mmol/L) or hypertriglyceridemia (&gt;500 mg/dL; &gt;8.5 mmol/L). Patients with controlled hyperlipidemia are acceptable. Diabetic patients Woman of childbearing potential who is planning to become pregnant or is pregnant and/or lactating who is unwilling to use effective means of contraception Presence of psychiatric illness (i.e., schizophrenia, major depression) that, in the opinion of the site investigator, would interfere with study requirements Any other medical condition that, in the opinion of the site investigator based on recall or chart review would interfere with completing the study Receiving any investigational drug or have received any investigational drug within 30 days prior to study enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Renal transplant, everolimus, cardiovascular profile, CNI-free immunosuppression, left ventricular hypertrophy, biopsy proved acute rejection (BPAR)</keyword>
</DOC>